CJC-1295 / Ipamorelin Blend – Research Compound Profile

CJC-1295 / Ipamorelin Blend – Research Compound Profile

Category: Hormonal Research | Molecular Type: Synthetic Peptide Blend (GHRH Analog + GH Secretagogue) | Research Status: Phase I/II Clinical Data (Individual Components)

This page compiles published research data for qualified researchers. CJC-1295 / Ipamorelin Blend is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation.

Purchase for Research →

Molecular Overview

Important distinction: The CJC-1295 component in this blend is the no-DAC form (Modified GRF 1–29). No Drug Affinity Complex is added — this is a genuinely different molecule from “CJC-1295 with DAC,” which carries a covalent albumin-binding moiety and a multi-day elimination half-life. Published pharmacokinetic data specific to the DAC-conjugated variant should not be read as describing this product.

CJC-1295 without DAC (Modified GRF 1-29) is a tetrasubstituted 29-amino acid synthetic analog of the first 29 amino acids of human growth hormone–releasing hormone (GHRH). Four strategic amino acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27) protect the molecule from rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its functional half-life to a duration of tens of minutes — substantially longer than native GHRH’s half-life of only a few minutes [1][2][16]. Unlike CJC-1295 with DAC, which conjugates to albumin and exhibits an elimination half-life measured in days [1], the no-DAC form used in this blend produces a short, pulsatile GH release profile that more closely mirrors endogenous GHRH signaling.

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide ghrelin mimetic that selectively activates the GH secretagogue receptor type 1a (GHS-R1a) — the same receptor targeted by the endogenous hormone ghrelin [3][17]. Raun et al. (1998) identified Ipamorelin as the first truly selective GHRP-receptor agonist: unlike GHRP-2 and GHRP-6, which significantly elevate ACTH and cortisol alongside GH, Ipamorelin produced no meaningful increase in ACTH, cortisol, prolactin, FSH, LH, or TSH across the dose range studied [3]. Pharmacokinetic modeling in healthy volunteers demonstrated a short terminal half-life on the order of a couple of hours, with peak GH observed within roughly the first hour post-administration [10].

The research rationale for combining these two peptides centers on their complementary receptor pathways. Co-administration of a GHRH-receptor agonist and a ghrelin-receptor agonist has been demonstrated to produce a synergistic GH response that significantly exceeds the mathematical sum of either agent alone [4][5]. This 1:1 blend (5 mg CJC-1295 no DAC + 5 mg Ipamorelin per 10 mg vial) represents one of the most widely investigated GH secretagogue pairings in current peptide research.

Mechanism of Action

CJC-1295 (no DAC) — GHRH Receptor Pathway

CJC-1295 (no DAC) binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating the Gs-adenylyl cyclase–cAMP–PKA signaling cascade. This opens voltage-gated calcium channels, triggers intracellular calcium influx, and stimulates exocytosis of stored growth hormone into the bloodstream [1][2][16]. Jetté et al. (2005) demonstrated in rats that CJC-1295 with DAC activates the GRF receptor on the anterior pituitary to stimulate GH release, characterizing it as a long-lasting GRF analog [16]; the underlying receptor-activation mechanism is shared by the no-DAC form used in this blend, though the DAC-conjugated molecule studied by Jetté et al. is not itself part of this product. Alba et al. (2006) showed that once-daily administration of CJC-1295 with DAC normalized growth parameters in a GHRH knockout mouse model, confirming the compound class’s functional role as a GHRH-receptor agonist [2]. Ionescu and Frohman (2006) further demonstrated that pulsatile GH secretion persists even during continuous stimulation by CJC-1295 with DAC, distinguishing GHRH-receptor agonism generally from exogenous GH administration, which flattens natural pulsatility [8]; for the short-acting no-DAC form used in this blend, pulsatility is preserved even more directly, since each dose clears rapidly and produces a single discrete pulse rather than sustained receptor occupancy.

Ipamorelin — GHS-R1a Receptor Pathway

Ipamorelin binds GHS-R1a in pituitary somatotrophs, triggering phospholipase C signaling, IP₃-mediated calcium release from intracellular stores, and subsequent GH exocytosis [3][17]. This pathway operates independently of the GHRH receptor. Raun et al. (1998) established Ipamorelin’s selectivity profile in swine models, demonstrating GH release potency comparable to GHRP-6 without concomitant elevations in ACTH, cortisol, or prolactin [3]. Van der Lely et al. (2004) reviewed the broader ghrelin-receptor physiology, confirming that GHS-R1a agonists such as Ipamorelin operate via distinct intracellular signaling mechanisms from GHRH-pathway compounds [17].

Dual-Pathway Activation

The pharmacological basis for combining these two peptides lies in their convergent but mechanistically independent actions on pituitary somatotrophs. Hataya et al. (2001) demonstrated in healthy male adults that ghrelin combined with GHRH stimulated GH in a statistically significant synergistic manner, with the combined response exceeding the additive individual responses [5]. Veldhuis and Keenan (2008) observed that GHRP-2 combined with GHRH produced a substantially greater increase in pulsatile GH secretion than either GHRP-2 or GHRH administered alone [9]. A 2014 review in PMC confirmed that ghrelin and GHRH, when administered simultaneously, exert a synergistic effect on GH secretion [4]. In this blend, CJC-1295 (no DAC) primes somatotroph cells via the GHRH receptor while Ipamorelin amplifies the resulting GH burst through the independent GHS-R1a pathway, producing a physiologically patterned GH pulse rather than a sustained non-physiologic plateau [2][18].

Published Research Parameters

The following table indexes the study models, compounds, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. Where a study used CJC-1295 with DAC rather than the no-DAC form contained in this blend, the compound is identified explicitly. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published literature and manufacturer technical resources report the following stability parameters for peptides of this class:

• Lyophilized stability: Lyophilized peptides stored sealed at −20 °C (−4 °F) remain stable for 24+ months when protected from moisture [12]. Long-term storage at this temperature is the standard recommendation for maintaining molecular integrity.
• Solution stability: Reconstituted peptide solutions stored at 2–8 °C (35.6–46.4 °F) maintain stability for up to 28 days [12]. Freeze-thaw cycles should be avoided, as ice crystal formation can fragment peptide bonds and compromise molecular integrity.
• Light sensitivity: Both CJC-1295 (no DAC) and Ipamorelin are susceptible to photodegradation. Published handling guidelines recommend storage in original packaging or light-protective wrapping [12].
• Reconstitution considerations: Agitation during reconstitution can denature peptide chains. Published protocols recommend gentle swirling rather than vigorous shaking, and directing solvent down the vessel wall rather than directly onto lyophilized material to minimize foaming [12].
• Contamination control: Each stopper puncture into a shared vial introduces a potential contamination pathway. Minimizing puncture frequency and maintaining aseptic technique during withdrawal is a standard laboratory practice for preserving solution sterility over the vial’s usable lifetime.
• Degradation chemistry: Both peptides in this blend are susceptible to deamidation at Gln/Asn-adjacent residues and to oxidation of susceptible side chains (e.g., His in Ipamorelin) under elevated temperature, extreme pH, or prolonged light exposure. These degradation pathways, rather than simple potency loss, account for most observed reductions in peptide-content assay results over time.

Analytical Characterization

Because this product is a two-component blend, analytical verification should confirm both the identity and the relative ratio of each peptide, not merely total peptide mass. Reverse-phase HPLC resolves CJC-1295 (no DAC) and Ipamorelin as distinct peaks based on their differing hydrophobicity, allowing independent purity assessment of each component and detection of any synthesis-related truncation or deamidation products. Electrospray mass spectrometry (ESI-MS) confirms the intact monoisotopic mass of each peptide independently, distinguishing the no-DAC CJC-1295 sequence from the substantially higher-mass DAC-conjugated variant should any conjugation contaminant be present. A peptide-content assay for each component, rather than gross lyophilizate weight, is the only reliable way to confirm the intended 1:1 mass ratio in a blended vial. Chiral/stereochemical purity assessment is relevant for Ipamorelin given its D-amino acid content (D-2Nal, D-Phe), where diastereomeric impurities from synthesis could otherwise co-elute or be mass-indistinguishable from the intended sequence without dedicated chiral methods.

Key Published Research Findings

• Dose-Dependent GH Elevation (CJC-1295 with DAC): In a 2006 Journal of Clinical Endocrinology & Metabolism study, Teichman et al. administered CJC-1295 with DAC to healthy adults and observed a statistically significant, dose-dependent increase in GH persisting for six or more days, with a corresponding IGF-1 elevation persisting 9–11 days [1]. This study evaluated the DAC-conjugated variant, not the no-DAC component of this blend.

• Sustained IGF-1 Elevation (CJC-1295 with DAC): In the same study, Teichman et al. reported that multiple-dose regimens of CJC-1295 with DAC maintained IGF-1 above baseline for up to 28 days, demonstrating cumulative pharmacodynamic effects with repeated administration of the long-acting form [1].

• Selective GH Secretion (Ipamorelin): In a 1998 European Journal of Endocrinology study, Raun et al. demonstrated in swine that Ipamorelin released GH with potency comparable to GHRP-6, without elevating ACTH, cortisol, or prolactin across the dose range tested, establishing Ipamorelin as the first selective GH secretagogue [3].

• Preserved Pulsatile GH Secretion (CJC-1295 with DAC): Ionescu and Frohman (2006) reported in Journal of Clinical Endocrinology & Metabolism that pulsatile GH secretion patterns persist even during continuous stimulation by CJC-1295 with DAC, a critical distinction from exogenous GH administration, which suppresses endogenous pulsatility [8].

• Synergistic GH Release (GHRH + Ghrelin Pathway): Hataya et al. (2001) demonstrated in healthy male adults that co-administration of ghrelin with GHRH produced a statistically significant synergistic GH secretion exceeding the additive sum of individual responses [5]. Veldhuis and Keenan (2008) observed a substantially greater increase in pulsatile GH secretion when GHRP-2 was combined with GHRH than either agent produced alone [9].

• Bone Growth Stimulation (Ipamorelin, animal model): In a 1999 Growth Hormone & IGF Research study, Andersen et al. demonstrated that Ipamorelin produced a statistically significant, dose-dependent increase in longitudinal bone growth rate in rats over a 15-day administration protocol [19].

• IGF-1 Response in GHS Combination Studies: Sigalos et al. (2017) reported in American Journal of Men’s Health that GH secretagogue combination therapy in hypogonadal men on testosterone therapy produced statistically significant increases in serum IGF-1 across the 270-day study period [20].

• Normalization of Growth in GHRH-Deficient Models (CJC-1295 with DAC): Alba et al. (2006) demonstrated in American Journal of Physiology – Endocrinology and Metabolism that once-daily administration of CJC-1295 with DAC normalized growth in GHRH knockout mice, confirming the GHRH-receptor pathway’s ability to restore GH axis function [2]. This finding demonstrates receptor-class biology and does not describe the pharmacokinetics of the no-DAC component used in this blend.

Safety Profile in Published Literature

Reported Adverse Events in Clinical Studies

• Injection-site reactions: Teichman et al. (2006) reported transient redness, mild swelling, or itching at the injection site as the most commonly observed adverse event in studies of CJC-1295 with DAC in healthy adults. These reactions were described as self-limiting [1].

• Flushing and warmth: Brief facial flushing or warmth post-administration has been noted in GH secretagogue studies, attributed to transient vasodilation associated with acute GH release [21].

• Headache: Occasional headache has been reported in GH secretagogue research, hypothesized to relate to acute changes in intracranial fluid dynamics secondary to GH elevation [20].

• Transient fluid retention: GH is known to promote sodium and fluid retention. Peripheral edema has been documented in the early phases of GH secretagogue studies, typically resolving with continued observation [21].

• Paresthesia: Tingling or numbness in extremities has been noted in GH-related studies, attributed to GH-mediated changes in fluid balance [21].

• Appetite effects: Raun et al. (1998) noted that Ipamorelin’s selectivity for GHS-R1a resulted in minimal appetite stimulation compared to non-selective GHRPs such as GHRP-6, which activate broader ghrelin-pathway signaling [3].

Toxicological Considerations

• Sigalos and Pastuszak (2018) reviewed the safety and efficacy profile of GH secretagogues and noted that the class generally demonstrates a favorable safety profile in published literature, though long-term safety data remains limited [18].
• GH secretagogues may influence insulin sensitivity and glucose metabolism. Published research has recommended metabolic monitoring (IGF-1, fasting glucose) in study protocols [6].

Regulatory Status

• FDA approval: Neither CJC-1295 (no DAC) nor Ipamorelin has been approved by the FDA for any therapeutic indication.
• Clinical trial status: Individual components and closely related compounds have been evaluated in Phase I/II clinical trials. CJC-1295 with DAC was studied by Teichman et al. (2006) in healthy adult volunteers [1]. Ipamorelin pharmacokinetics were characterized in healthy volunteers by Agersø et al. (1999) [10].
• Research-only classification: This compound is sold exclusively for research purposes and is not intended for human consumption, veterinary use, self-administration, or any therapeutic application.

References

1. J Clin Endocrinol Metab (2006) — Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” View Source

2. Am J Physiol Endocrinol Metab (2006) — Alba M, Fintini D, Sagazio A, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” View Source

3. Eur J Endocrinol (1998) — Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” View Source

4. PMC (2014) — Ghrelin as a Regulatory Peptide in Growth Hormone Secretion. “Ghrelin and GHRH when administered simultaneously has a synergistic effect on the secretion of GH.” View Source

5. J Clin Endocrinol Metab (2001) — Hataya Y, Akamizu T, Takaya K, et al. “A low dose of ghrelin stimulates growth hormone (GH) release synergistically combined with GH-releasing hormone in humans.” View Source

6. Transl Androl Urol (2020) — Sinha DK, Balasubramanian A, Tatem AJ, et al. “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.” View Source

7. J Clin Endocrinol Metab (1991) — Van Cauter E, Plat L. “Physiology of growth hormone secretion during sleep.” View Source

8. J Clin Endocrinol Metab (2006) — Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” View Source

9. Eur J Endocrinol (2008) — Veldhuis JD, Keenan DM. “Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men.” View Source

10. Pharm Res (1999) — Agersø H, Møller-Pedersen J, Cappi S, et al. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in healthy volunteers.” View Source

11. Physiol Rev (2004) — Kojima M, Kangawa K. “Ghrelin: Structure and Function.” (Discusses somatostatin-mediated GH suppression in fed states.) View Source

12. GenScript Technical Resources — Peptide Handling and Storage Guidelines. “Lyophilized peptides should be stored at −20 °C and are stable for 24+ months.” View Source

16. Endocrinology (2005) — Jetté L, Léger R, Thibaudeau K, et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” View Source

17. Endocrine Rev (2004) — Van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. “Ghrelin and growth hormone secretagogues: physiology and applications.” View Source

18. Sex Med Rev (2018) — Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” View Source

19. Growth Horm IGF Res (1999) — Andersen NB, Malmlöf K, Johansen PB, et al. “Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.” View Source

20. Am J Mens Health (2017) — Sigalos JT, Pastuszak AW, Allison A, et al. “Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.” View Source

21. Front Endocrinol (2019) — Growth Hormone Secretagogues: History and Clinical Applications. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The CJC-1295 component of this blend is the no-DAC form; no Drug Affinity Complex is added. CJC-1295 / Ipamorelin Blend is sold exclusively as a research compound and has not been approved by the FDA for human consumption or use. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase CJC-1295 / Ipamorelin Blend for Research →